Curocell’s Homegrown CAR-T Therapy Rimqarto Lands Spotlight in Top Hematology Journal Blood
Curocell, a South Korean clinical-stage biotech company specializing in chimeric antigen receptor T-cell (CAR-T) therapies, announced on June 15 that...
Search results for "chimeric antigen receptor"
Samsung Medical Center Ranks No. 5 Globally for Cancer Care in Newsweek 2027 Assessment, Climbing to No. 12 in Respiratory Medicine
Samsung Medical Center has been named the No. 5 hospital worldwide and No. 1 in South Korea for cancer treatment, according to the "World's Best...
South Korea’s First Homegrown CAR-T, Rimqarto, Moves Closer to Coverage with 67% Complete Response Rate
Curocell announced on Sept. 4 that its chimeric antigen receptor T-cell (CAR-T) therapy Rimqarto (generic name:...
Gachon University Gil Medical Center Expands Advanced Blood Cancer Care as Regional CAR-T Center Reaches Two-Year Milestone
For patients with aggressive blood cancers that recur or fail to respond to standard chemotherapy, chimeric antigen...
CAR-T Without Extracting Patient Cells? J&J Makes $785 Million Bet on In Vivo Therapy
Johnson & Johnson (J&J) is investing more than $785 million (approximately 1.11 trillion won) in next-generation "in...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...
Rznomics and Inha University Confirm Potential for In-Vivo CAR-T Delivery Technology
Rznomics announced on the 30th that a joint study with Professor Hyun-jin Kim’s research team at Inha University has...
Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?
A final decision on the approval of RIMQARTO (anbalcabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T)...
1